热门资讯> 正文

Nuvation Bio，Nurai治疗非小细胞肺癌的申请已被EMA接受

2026-03-27 05:26

EISAI CO(ESALF) 0
EISAI CO UNSPON ADS EACH REP 1 ORD(ESAIY) 0
高宏集团(COWN) 0

The European Medicines Agency has accepted a Marketing Authorisation Application filed by Nuvation Bio (NUVB) and Eisai (ESALF)(ESAIY) for taletrectinib to treat non-small cell lung cancer.
The application was given a standard review time of 210 "active" days. It is supported by data from two pivotal phase 2 studies, TRUST-I and TRUST-II.
Taletrectinib is already marketed as Ibtrozi in the US and Japan.

More on Nuvation Bio, Eisai

Nuvation Bio Inc. (NUVB) Presents at The Citizens Life Sciences Conference 2026 Transcript
Nuvation Bio Inc. (NUVB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript
Eli Lilly, Biogen/ Eisai win U.K. review for use of Alzheimer’s drugs in NHS
Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。